The Post and Courier reports that MUSC is testing its Moodivate app in a clinical trial involving cancer patients, a group in which depression can affect up to 40 percent.
MUSC study examines an app for low mood
The Post and Courier reports that MUSC is running a clinical trial of its Moodivate app with cancer patients. The source describes the trial as testing the app with people who have cancer.
The Post and Courier reports that depression affects up to 40 percent of cancer patients. The source links the Moodivate trial to depression and low mood among people receiving cancer care.
What the source says about the trial
According to The Post and Courier, MUSC created the Moodivate app and is now testing it in a clinical trial involving cancer patients. The extract does not say how many patients are taking part in the trial.
The Post and Courier’s extract does not describe the app’s features, how participants use it, or how long the clinical trial will run. The extract also does not report trial results or whether the app has been shown to improve depression or low mood.
Depression and cancer care
The Post and Courier identifies depression as an issue that can affect cancer patients, reporting that it affects up to 40 percent of people in that group. The source presents the Moodivate clinical trial as an effort involving cancer patients and an app focused on mood.
The source extract does not state whether the app is intended to replace other mental health services. It also does not state whether the app is available outside the clinical trial or whether people can enroll independently.
What this means for South Carolina patients
The Post and Courier’s report highlights a MUSC clinical trial involving mood support for cancer patients. South Carolinians looking for treatment locally can use the directory, which lists 35 published clinics in South Carolina, to identify treatment options and discuss appropriate care with a qualified professional.
This is general information, not medical advice.
More South Carolina reporting on treatment updates.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.